Study S000422

Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07401992
Acronym: SEMAPSO
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 62
Start: 2026-01-15
Primary completion: 2027-02-28
Lead sponsor: Hospital Universitario Dr. Jose E. Gonzalez
Conditions: Psoriasis (PsO); Obesity & Overweight; Diabetes Mellitus - Type 2
Interventions: DRUG:Semaglutide (Rybelsus®); DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Effect of GLP-1 Receptor Agonists on SCD-1 Activity [Baseline to Week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.